CA2697159C - Antibodies to cd200 and uses thereof in inhibiting immune responses - Google Patents

Antibodies to cd200 and uses thereof in inhibiting immune responses Download PDF

Info

Publication number
CA2697159C
CA2697159C CA2697159A CA2697159A CA2697159C CA 2697159 C CA2697159 C CA 2697159C CA 2697159 A CA2697159 A CA 2697159A CA 2697159 A CA2697159 A CA 2697159A CA 2697159 C CA2697159 C CA 2697159C
Authority
CA
Canada
Prior art keywords
antibody
cells
antibodies
antigen
graft
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2697159A
Other languages
English (en)
French (fr)
Other versions
CA2697159A1 (en
Inventor
Russell P. Rother
Susan Faas Mcknight
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of CA2697159A1 publication Critical patent/CA2697159A1/en
Application granted granted Critical
Publication of CA2697159C publication Critical patent/CA2697159C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2697159A 2007-07-25 2008-07-25 Antibodies to cd200 and uses thereof in inhibiting immune responses Expired - Fee Related CA2697159C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96202207P 2007-07-25 2007-07-25
US60/962,022 2007-07-25
PCT/US2008/009037 WO2009014745A1 (en) 2007-07-25 2008-07-25 Antibodies to cd200 and uses thereof in inhibiting immune responses

Publications (2)

Publication Number Publication Date
CA2697159A1 CA2697159A1 (en) 2009-01-29
CA2697159C true CA2697159C (en) 2017-02-14

Family

ID=40001380

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2697159A Expired - Fee Related CA2697159C (en) 2007-07-25 2008-07-25 Antibodies to cd200 and uses thereof in inhibiting immune responses

Country Status (9)

Country Link
US (3) US8252285B2 (https=)
EP (1) EP2178561A1 (https=)
JP (4) JP2010534243A (https=)
KR (1) KR20100041849A (https=)
AU (1) AU2008279619B2 (https=)
BR (1) BRPI0814644A2 (https=)
CA (1) CA2697159C (https=)
MX (1) MX2010000981A (https=)
WO (1) WO2009014745A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252285B2 (en) 2007-07-25 2012-08-28 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof in inhibiting immune responses
WO2011100538A1 (en) 2010-02-11 2011-08-18 Alexion Pharmaceuticals, Inc. Therapeutic methods using an ti-cd200 antibodies
AU2012212066A1 (en) * 2011-02-03 2013-08-15 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
US9309305B2 (en) 2011-06-10 2016-04-12 National Research Council Of Canada Anti-ricin antibodies and uses thereof
EP2723380B1 (en) 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
US9737598B2 (en) 2014-06-30 2017-08-22 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
CA2969384A1 (en) * 2014-12-17 2016-06-23 Cellectis Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain
US10888609B2 (en) 2015-11-03 2021-01-12 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
WO2018102594A1 (en) * 2016-12-01 2018-06-07 Alexion Pharmaceuticals, Inc. Methods of treating solid tumors with anti-cd200 antibodies
KR101968246B1 (ko) * 2017-04-27 2019-04-11 서울대학교산학협력단 이종 각막 이식에서 항 cd20 단일클론항체 및 타클로리무스의 복합면역억제 방법
US11761963B2 (en) 2017-09-27 2023-09-19 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-CD200 therapy
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
WO2019126133A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-cd200 antibodies
US12414983B2 (en) 2019-01-14 2025-09-16 Regents Of The University Of Minnesota CD200AR ligands for cancer immunotherapy
EP4296280A1 (en) 2022-06-21 2023-12-27 F. Hoffmann-La Roche AG Cd123 and cd200 as markers for the diagnosis and immune-eradication of leukemic stem cells (lscs)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223729B2 (en) * 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
EP1032662B1 (en) * 1997-11-07 2006-03-08 Trillium Therapeutics Inc. Methods and compositions for immunomodulation
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
MXPA05006978A (es) 2002-12-27 2005-08-16 Schering Corp Metodos para inducir y mantener la tolerancia inmune.
HUE028179T2 (en) * 2006-01-12 2016-12-28 Alexion Pharma Inc Antibodies to OX-2 / CD200 and their use
WO2009014744A1 (en) 2007-07-25 2009-01-29 Alexion Pharmaceutical, Inc. Methods and compositions for treating autoimmune disease
US8252285B2 (en) * 2007-07-25 2012-08-28 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof in inhibiting immune responses

Also Published As

Publication number Publication date
AU2008279619B2 (en) 2013-11-14
EP2178561A1 (en) 2010-04-28
JP2013163695A (ja) 2013-08-22
US20100291085A1 (en) 2010-11-18
USRE46323E1 (en) 2017-02-28
BRPI0814644A2 (pt) 2015-01-27
WO2009014745A1 (en) 2009-01-29
CA2697159A1 (en) 2009-01-29
KR20100041849A (ko) 2010-04-22
JP2016117762A (ja) 2016-06-30
US8252285B2 (en) 2012-08-28
US8637014B2 (en) 2014-01-28
US20120321625A1 (en) 2012-12-20
JP2010534243A (ja) 2010-11-04
AU2008279619A1 (en) 2009-01-29
JP5926702B2 (ja) 2016-05-25
MX2010000981A (es) 2010-05-21
JP2015172090A (ja) 2015-10-01

Similar Documents

Publication Publication Date Title
CA2697159C (en) Antibodies to cd200 and uses thereof in inhibiting immune responses
US8709415B2 (en) Antibodies to OX-2/CD200 and uses thereof
EP2040730B1 (en) Modulation of nkg2d in hbv patients
US20070148162A1 (en) Molecule which binds cd80 and cd86
JP2023016923A (ja) 調節性ｔ細胞及びその使用
US8986684B2 (en) Methods and compositions for treating autoimmune disease
WO2009026472A1 (en) Methods for inducing tolerance
WO2004002425A2 (en) Process for promoting graft acceptance by depletion of hematopoietic stem cells
WO1995015340A1 (en) Monoclonal antibodies to antigens expressed by human dendritic cells
EP3575320A1 (en) New therapy for treating graft-versus-host-disease
US20240279353A1 (en) Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
JP2025066696A (ja) 移植片対宿主病（ＧｖＨＤ）の防止又は処置のための抗ＣＣＲ７ ＭＡＢの使用
KR100975042B1 (ko) 스테로이드-내성 환자에서의 ｃｄ25 결합 분자의 용도
AU2014200678A1 (en) Antibodies to CD200 and uses thereof in inhibiting immune responses
US20240190965A1 (en) Targeting anti-human pd 1h/vista to treat hematologic disorders
JP2024532167A (ja) 抗ｆｌｔ３抗体、ｃａｒ、ｃａｒ ｔ細胞、及び使用方法
HK40109251A (zh) 用抗pd-1抗体和抗cd30抗体-药物缀合物的组合治疗癌症的方法
EA050337B1 (ru) Применение мат против ccr7 для предотвращения или лечения реакции "трансплантат против хозяина" (ртпх)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130716

MKLA Lapsed

Effective date: 20200831